Idinvest Partners and Kurma Partners sell Prosensa to BioMarin for up to USD840m
Benoist Grossmann, Managing Partner of Idinvest Partners, says:
“The healthcare sector weighs approximately a quarter of Idinvest’s growth capital portfolio, alongside the digital and environmental technology industries.
Prosensa, a specialist in the discovery and development of innovative therapies, has reported highly encouraging results in the treatment of Duchenne muscular dystrophy. Duchenne muscular dystrophy is a disorder that affects 150 to 200 new-born males every year in France. Around 2,500 people are affected by the disease across the country. This deal demonstrates Idinvest’s drive to support tangible and innovative projects that will play a key role in shaping tomorrow’s world”.